Search Results
Apr 15, 2026, 09:15 ET Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6.
More news about: Intensity Therapeutics Inc.
Apr 14, 2026, 12:59 ET Bridge Defense Acquires Syntelligent Analytic Solutions to Expand Intelligence and Analytics Capabilities
acquisition expands Bridge Defense's capabilities across the intelligence lifecycle, combining Syntelligent's expertise in all-source analysis, multi-INT operations, and geospatial and cyber analytics with Bridge Defense's strengths in software development, infrastructure, and deployable systems. Together,
More news about: Bridge Defense
Apr 09, 2026, 08:00 ET Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Eisai Co., Ltd. E2086, A Selective Orexin Receptor-2
More news about: Eisai Inc.
Apr 08, 2026, 08:03 ET Supira Medical Anuncia Aprovação da FDA para o Estudo Pivotal SUPPORT II, Avanços em Choque Cardiogênico e Nomeação de D. Keith Grossman para o Conselho de Administração
O SUPPORT II (SUpira System in Patients Undergoing High-Risk Percutaneous C OronaRy InT ervention (HRPCI)) é um estudo prospectivo, randomizado e controlado projetado para avaliar a segurança e a eficácia do pVAD de próxima geração
More news about: Supira Medical, Inc.
Apr 08, 2026, 08:03 ET Supira Medical anuncia la aprobación de la FDA para el ensayo pivotal SUPPORT II, los avances en el shock cardiogénico y el nombramiento de D. Keith Grossman como miembro de la junta directiva
SUPPORT II (SUpira System in Patients Undergoing High-Risk P ercutaneousCOronaRe InT ervention (HRPCI)) es un estudio prospectivo, aleatorizado y controlado diseñado para evaluar la seguridad y eficacia del pVAD de próxima generación
More news about: Supira Medical, Inc.
Apr 06, 2026, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Ponto KA, et al. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106(17):283-289.5
More news about: Amgen
Apr 06, 2026, 03:25 ET CS Analytical to Exhibit at Interphex 2026 - Highlighting Expanded Service Offering
https://interphex26.nvytes.co/interphexinvite2026/INT26CIP106.html
More news about: CS Analytical
Apr 02, 2026, 13:25 ET Funded, Permitted, and Building: The Gold Developers That Didn't Wait
https://capital.com/en-int/market-updates/gold-price-forecast-03-03-2026
More news about: USA News Group
Apr 02, 2026, 11:00 ET GECU Announces New $300 Checking Account Bonus
Percentage Yield (APY) of 0.10% is accurate as of February 18, 2026, and may change after the account is opened. Bonus will be reported on IRS Form 1099-INT (or Form 1042-S, if applicable).2Must have a GECU share account to open a checking account. Open a GECU share account with a one-time
More news about: GECU
Apr 01, 2026, 07:06 ET GFT Technologies Positioned as a Leader in the SPARK Matrix™: Insurance Digital Transformation Services, 2026 by QKS Group
www.gft.com www.gft.com/int/en/blogwww.linkedin.com/company/gft-technologies Media
More news about: QKS Group
Mar 27, 2026, 16:12 ET Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
December 31, 2025, cash and cash equivalents totaled $11.9 million.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Mar 26, 2026, 19:12 ET Axi 推出由 Kathy Lien 主持的 Podcast 節目《The Strategy Room》
[email protected]有關 Axi Select 計劃的所有詳情，請瀏覽：https://www.axi.com/int/funded-trader-programAxi Select 計劃只適用於 AxiTrader LLC 的客戶。 差價合約 (CFD) 涉及高風險，投資可能造成損失。 此內容或未能在您所在的地區瀏覽。
More news about: AxiTrader
Mar 26, 2026, 19:08 ET Axi lança podcast "The Strategy Room" apresentando por Kathy Lien
detalhes do programa Axi Select, acesse: https://www.axi.com/int/funded-trader-programO programa Axi Select está disponível apenas para clientes da AxiTrader LLC. Os CFDs apresentam um alto risco de perda de
More news about: AxiTrader
Mar 26, 2026, 19:06 ET Axi presenta el podcast "The Strategy Room" presentado por Kathy Lien
sobre el programa Axi Select, visite: https://www.axi.com/int/funded-trader-programEl programa Axi Select solo está disponible para clientes de AxiTrader LLC. Los CFD conllevan un gran riesgo de pérdida
More news about: AxiTrader
Mar 26, 2026, 12:30 ET 액시, 캐시 리엔 진행 '더 스트래티지 룸' 팟캐스트 출시
[email protected]액시 셀렉트 프로그램에 대한 자세한 내용은 https://www.axi.com/int/funded-trader-program에서 확인할 수 있다.액시 셀렉트 프로그램은 액시트레이더(AxiTrader LLC)의 고객에게만 제공된다. CFD 거래는 높은 투자 손실 위험을 수반한다. 본 콘텐츠는 일부 지역에서는 제공되지 않을 수 있다. 자세한
More news about: AxiTrader
Mar 25, 2026, 18:31 ET Axi startet „The Strategy Room"-Podcast mit Host Kathy Lien
das Axi Select Programm finden Sie auf: https://www.axi.com/int/funded-trader-programDas Axi Select-Programm ist nur für Kunden der AxiTrader LLC verfügbar. CFDs bergen ein hohes Verlustrisiko für Anlegerinnen
More news about: AxiTrader
Mar 25, 2026, 10:53 ET Axi lance le podcast « The Strategy Room » animé par Kathy Lien
programme Axi Select, visitez le site : https://www.axi.com/int/funded-trader-programLe programme Axi Select est uniquement disponible pour les clients d'AxiTrader LLC. Les CFD comportent un risque élevé de
More news about: AxiTrader
Mar 25, 2026, 09:31 ET Axi、「The Strategy Room」ポッドキャストを開始、キャシー・リーン氏がホストを担当
[email protected] Selectプログラムの詳細については、以下をご覧ください：https://www.axi.com/int/funded-trader-programAxi Selectプログラムは、AxiTrader LLCの顧客のみが利用可能です。CFD（差金決済取引）は高い損失リスクを伴います。本コンテンツは、お住まいの地域ではご利用いただけない場合があります。詳細については、当社の利用規約をご参照ください。通常の取引手数料および最低入金額が適用されます。ロゴ
More news about: AxiTrader
Mar 25, 2026, 09:23 ET Axi lanza el podcast "The Strategy Room" presentado por Kathy Lien
detalles del programa Axi Select, visite: https://www.axi.com/int/funded-trader-programEl programa Axi Select sólo está disponible para clientes de AxiTrader LLC. Los CFD conllevan un alto riesgo de pérdida
More news about: AxiTrader
Mar 25, 2026, 09:00 ET Axi Launches "The Strategy Room" Podcast Hosted by Kathy Lien
details on the Axi Select program, visit: https://www.axi.com/int/funded-trader-programThe Axi Select program is only available to clients of AxiTrader LLC. CFDs carry a high risk of investment loss. This content
More news about: AxiTrader
Mar 25, 2026, 09:00 ET Axi Launches "The Strategy Room" Podcast Hosted by Kathy Lien
details on the Axi Select program, visit: https://www.axi.com/int/funded-trader-programThe Axi Select program is only available to clients of AxiTrader LLC. CFDs carry a high risk of investment loss. This content
More news about: AxiTrader
Mar 24, 2026, 09:03 ET Xtressé™ Announces FDA IND Acceptance for Xvie, The First & Only Extracellular Vesicle Injectable Therapy for Androgenetic Alopecia
exosomes carrying MiR-122-5p antagonize the inhibitory effect of dihydrotestosterone on hair follicles by targeting the TGF-β1/SMAD3 signaling pathway. Int J Mol Sci. 2023;24(6):5703.⁸ Zhou L, Wang H, Jing J, et al. Regulation of hair follicle development by exosomes derived from dermal papilla
More news about: Xtressé™
Mar 24, 2026, 08:00 ET Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
by us and not acquired from in-licensing from any third party.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Mar 20, 2026, 12:05 ET Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Mar 18, 2026, 10:00 ET High-Margin Mining: How the Smart Money Is Navigating the New Gold Supercycle
https://capital.com/en-int/market-updates/gold-price-forecast-13-03-2026
More news about: USA News Group